SE460457B - Stabil, fast och vattenloeslig farmaceutisk komposition innehaallande 4'-(9-akridinylamino)-metansulfon-m-anisidid (m-amsa) - Google Patents

Stabil, fast och vattenloeslig farmaceutisk komposition innehaallande 4'-(9-akridinylamino)-metansulfon-m-anisidid (m-amsa)

Info

Publication number
SE460457B
SE460457B SE8103071A SE8103071A SE460457B SE 460457 B SE460457 B SE 460457B SE 8103071 A SE8103071 A SE 8103071A SE 8103071 A SE8103071 A SE 8103071A SE 460457 B SE460457 B SE 460457B
Authority
SE
Sweden
Prior art keywords
amsa
lactic acid
water
solid
solution
Prior art date
Application number
SE8103071A
Other languages
English (en)
Swedish (sv)
Other versions
SE8103071L (sv
Inventor
M A Kaplan
D Bouzard
C Perol
J Stemer
A Weber
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of SE8103071L publication Critical patent/SE8103071L/
Publication of SE460457B publication Critical patent/SE460457B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE8103071A 1980-05-16 1981-05-15 Stabil, fast och vattenloeslig farmaceutisk komposition innehaallande 4'-(9-akridinylamino)-metansulfon-m-anisidid (m-amsa) SE460457B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/147,056 US4360523A (en) 1980-05-16 1980-05-16 Pharmaceutical formulations of 4'-(9-acridinylamino)-methanesulfon-m-anisidide

Publications (2)

Publication Number Publication Date
SE8103071L SE8103071L (sv) 1981-11-17
SE460457B true SE460457B (sv) 1989-10-16

Family

ID=22520148

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8103071A SE460457B (sv) 1980-05-16 1981-05-15 Stabil, fast och vattenloeslig farmaceutisk komposition innehaallande 4'-(9-akridinylamino)-metansulfon-m-anisidid (m-amsa)

Country Status (21)

Country Link
US (1) US4360523A (fi)
JP (1) JPS579716A (fi)
AT (1) AT374682B (fi)
AU (1) AU543726B2 (fi)
BE (1) BE888832A (fi)
CA (1) CA1160571A (fi)
CH (1) CH647677A5 (fi)
DE (1) DE3119510A1 (fi)
DK (1) DK159376C (fi)
FI (1) FI70793C (fi)
FR (1) FR2482458A1 (fi)
GB (1) GB2076288B (fi)
GR (1) GR75658B (fi)
IE (1) IE51285B1 (fi)
IT (1) IT1170970B (fi)
LU (1) LU83363A1 (fi)
NL (1) NL8102362A (fi)
NZ (1) NZ196985A (fi)
SE (1) SE460457B (fi)
YU (1) YU44831B (fi)
ZA (1) ZA813188B (fi)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575509A (en) * 1983-01-31 1986-03-11 Bristol-Myers Company Water-soluble formulations of m-AMSA with pyroglutamic acid
US4626541A (en) * 1985-09-12 1986-12-02 Bristol-Myers Company Water soluble salt composition of m-AMSA
DE3844518A1 (de) * 1988-03-23 1989-10-05 Karl Heinz Dr Med Thiel Verwendung von aminochinolinen und aminopyridinen zur iontophoretischen behandlung maligner tumore
DE3819842C1 (fi) * 1988-03-23 1989-12-21 Karl Heinz Dr. 7100 Heilbronn De Thiel
CA2143515A1 (en) * 1994-03-22 1995-09-23 Prakash Parab Method for enhancing the rate of skin permeation of lactic acid through use of the l-enantiomer
DE102004031538A1 (de) * 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
WO2006002887A1 (en) * 2004-06-29 2006-01-12 Baxter International Inc. Aqueous drink solution of indibulin (d-24851) and an organic acid
CA2587276A1 (en) * 2004-11-08 2006-05-18 Baxter International Inc. Nanoparticulate compositions of tubulin inhibitor compounds
EP2091532A1 (en) * 2006-11-28 2009-08-26 Ziopharm Oncology, Inc. Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
EP3154538B1 (en) * 2014-03-31 2024-06-05 Teymuras Kurzchalia Glycolic acid and/or d-lactic acid for the treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
DE3119510C2 (fi) 1991-03-07
NZ196985A (en) 1983-06-17
LU83363A1 (fr) 1982-01-20
IE811092L (en) 1981-11-16
AU543726B2 (en) 1985-05-02
BE888832A (fr) 1981-11-16
AT374682B (de) 1984-05-25
IE51285B1 (en) 1986-11-26
SE8103071L (sv) 1981-11-17
CH647677A5 (de) 1985-02-15
ATA221181A (de) 1983-10-15
AU7029181A (en) 1981-11-19
IT1170970B (it) 1987-06-03
GB2076288A (en) 1981-12-02
YU44831B (en) 1991-04-30
DK216681A (da) 1981-11-17
GB2076288B (en) 1983-12-14
CA1160571A (en) 1984-01-17
US4360523A (en) 1982-11-23
GR75658B (fi) 1984-08-02
DK159376C (da) 1991-03-25
JPH0136445B2 (fi) 1989-07-31
DK159376B (da) 1990-10-08
FI70793C (fi) 1986-10-27
FR2482458A1 (fr) 1981-11-20
NL8102362A (nl) 1981-12-16
FI811474L (fi) 1981-11-17
DE3119510A1 (de) 1982-02-25
FR2482458B1 (fi) 1984-12-14
JPS579716A (en) 1982-01-19
IT8148467A0 (it) 1981-05-14
FI70793B (fi) 1986-07-18
ZA813188B (en) 1982-05-26
YU112381A (en) 1985-03-20

Similar Documents

Publication Publication Date Title
US6673805B2 (en) Platinum derivative pharmaceutical formulations
JP4890732B2 (ja) 癌治療用パクリタキセル・リポソーム組成物およびその製造方法
JPH0354089B2 (fi)
SE460457B (sv) Stabil, fast och vattenloeslig farmaceutisk komposition innehaallande 4'-(9-akridinylamino)-metansulfon-m-anisidid (m-amsa)
WO2013071696A1 (zh) 人体五种正常碱基在制备肿瘤药物中的应用
JPS604802B2 (ja) 制癌剤
ES2280259T3 (es) Complejos de galio de 3-hidroxi-4-pironas para tratar infecciones por procariotas intracelulares, virus de adn y retrovirus.
US20090117205A1 (en) Quinolone-containing medicinal composition
KR890001236B1 (ko) 소염제 조성물의 제조방법
GB2030863A (en) Antibacterial compositions
US4425348A (en) Antitumor compositions
US4892876A (en) Method for inhibiting HIV and an pharmaceutical composition therefor
WO2016199053A1 (en) Stable liquid formulations of pemetrexed
JPH11508566A (ja) リファブチンを含む抗細菌相乗性組成物
JPH0343251B2 (fi)
EP0830862A1 (en) Anti-hiv drugs
CA1285226C (en) Compositions containing a 2,4-diamino-pyrimidine and sulphadimidine
JPS5938207B2 (ja) 腎疾患治療剤
JP2003509356A (ja) リン酸エストラムスチン塩およびスルホアルキルエーテルシクロデキストリンの非経口的使用のための処方
US4626541A (en) Water soluble salt composition of m-AMSA
JPH01313433A (ja) 抗ｈｉｖ剤
JPH04108731A (ja) 抗エイズウイルス剤
CN116966183A (zh) 一种药物组合物及其在制备抗前列腺癌药物中的应用
JP2643340B2 (ja) ヒト後天性免疫不全症候群ウイルス感染阻害剤
JP3064027B2 (ja) 血管新生阻害剤

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 8103071-0

Effective date: 19911209

Format of ref document f/p: F